Body shape and metabolic abnormalities in Thai HIV-infected patients.
Body shape and metabolic abnormalities in Thai HIV-infected patients.
复制标题
泰国艾滋病毒感染者的体型和代谢异常。
DOI：
10.1089/aid.2007.0013
复制
发表时间：
2007
影响因子：
1.5
通讯作者：
CofrancescoJr,Joseph
中科院分区：
文献类型：
--
作者：
Homsanit,Mayuree;Nelson,KenradE;Sonjai,Areeuea;Anekthananon,Thanomsak;Suwanagool,Surapol;CofrancescoJr,Joseph
对泰国HIV感染者的脂肪和代谢异常及其相关因素进行了检测。对247名感染HIV的泰国人的体脂和空腹血脂(总胆固醇，TC；甘油三酯，TG；高密度脂蛋白胆固醇，HDLc)进行了评估。体脂由受试者和盲目观察者评估，并用双能X射线吸收计量仪测量。采用描述性统计和Logistic回归分析。与未接受抗逆转录病毒(ARV)治疗的受试者相比，接受抗逆转录病毒(ARV)治疗的泰国人明显年龄更大，更有可能是男性，并且有更高的教育和收入。脂肪萎缩的患病率在未服用抗逆转录病毒药物的患者中为10.3%，在接受非蛋白酶抑制剂(PI)抗逆转录病毒治疗的患者中为36.7%，在接受抗逆转录病毒药物治疗的患者中为78.7%(p<；0.001)。幼稚组、非PI组和PI组的腹部或颈部脂肪过多的比例分别为0.8%、6.7%和24.6%(p<；0.001)。高胆固醇血症(TC-HDL240 mg/dl)分别为4.8%、26.6%和42.6%，高甘油三酯血症(TG-≥150 mg/dl)分别为8.2%、48.3%和75.4%，低≥-c(40 mg/dl)分别为42.9%、20.0%和31.2%。中心脂肪与外周脂肪的比值分别为1.11±0.03、1.45±0.06和1.93±0.08(p<；0.001)。治疗与异常脂肪有关。脂肪过多引起脂肪萎缩的调整OR(95%CI)为4.6(2.0~10.7)、6.3(0.6~71.1)、5.6(3.4~9.1)、10.7(3.4~33.8)、5.7(2.4~13.9)、5.3(1.2~11.4~13.9)。ARV相关的代谢异常在非西方人群中很常见。ARV治疗的适当选择和监测对于将长期并发症的风险降至最低至关重要。
Fat and metabolic abnormalities and their associated factors in HIV-infected patients in Thailand were examined. Body fat and fasting lipids (total cholesterol, TC; triglyceride, TG; and HDL-cholesterol, HDL-c) were evaluated in 247 HIV-infected Thais. Body fat was evaluated by subjects and blinded observers, and measured using dual-energy X-ray absorptiometry. Descriptive statistics and logistic regression were used for analyses. Antiretroviral (ARV)-treated Thais were significantly older, more likely to be male, and had higher education and income compared to untreated subjects. The prevalence of lipoatrophy was 10.3% in ARV-naive patients, 36.7% in patients receiving non-protease inhibitor (PI)-based ARV, and 78.7% in PI-based ARV-treated patients (p< 0.001). Excess abdominal or neck fat was found in 0.8%, 6.7%, and 24.6% of the naive, non-PI-treated, and PI-treated, respectively (p< 0.001). Hypercholesterolemia (TC ≥ 240 mg/dl) was found in 4.8%, 26.6%, and 42.6%; hypertriglyceridemia (TG ≥ 150 mg/dl) in 8.2%, 48.3%, and 75.4%; and low HDL-c (HDL-c < 40 mg/dl) in 42.9%, 20.0%, and 31.2% of the naive, non-PI treated, and PI-treated, respectively (p< 0.05 for all). Central to peripheral fat ratios were 1.11 ± 0.03, 1.45 ± 0.06, and 1.93 ± 0.08 for the naive, non-PI, and PI-treated, respectively (p< 0.001). Treatment was associated with abnormal fat. The adjusted ORs (95% CI) of lipoatrophy for excess fat were 4.6 (2.0–10.7); 6.3 (0.6–71.1) for ARV-naive vs. non-PI; 5.6 (3.4–9.1); 10.7 (3.4–33.8) for ARV-naive vs. PI, and 5.7 (2.4–13.9); 5.3 (1.2–11.4–13.9) for ARV-naive vs. PI. ARV-associated metabolic abnormalities are common in this non-Western population. Appropriate selection and monitoring of ARV treatment are critical to minimize the risk of long-term complications.